Drug Profile


Alternative Names: BBR 3576

Latest Information Update: 09 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Therapeutics
  • Class Antineoplastics
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastric cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 31 Aug 2005 Topixantrone is available for partnering (
  • 07 Jan 2004 Novuspharma has merged with and into Cell Therapeutics
  • 09 Oct 2003 Data presented at the 12th European Cancer Conference (ECCO-2003) have been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top